Not concerned with it at alll myself. The CEO is a

Not concerned with it at alll myself. The CEO is as frugal with capital as I have ever seen. He only taps the funding when absolutely necessary. When he took over Cellceutix had around $5000 dollars in the bank. Now its in the millions and CTIX has three drugs in four trials while building that cash reserve. They don't have hundreds of employees drawing salaries and burning through cash like some other companies. The timing and amount of stock issued is entirely controlled by Cellceutix and the CEO has proven so far to be very adept at stretching every penny to keep the trials progressing. His history has shown that he usually comes in under the budgeted amounts on the previous clinical trials. This is their third agreement by the way 10, 20, now 30 million, if I recall correctly. The stock price has only recently declined and it coincided with the Mako/Rosen short attack, if that goes away I believe Cellceutix will uplist to Nasdaq within two weeks from that date. If you are not familiar with the Mako piece you should read this link.
http://finance.yahoo.com/news/cellceutix-prov...20127.html

It should be obvious to you that this was an orchestrated attack that is based on false/misleading facts. Rosen filed their suit within 2 hours.
This type of suit can (should) be filed after many months/years of due diligence to varify facts. It seems almost certain that there were nefarious activities by Mako, Rosen or both. As with any Biotech stock the largest gamble is if the drug works and gets approved for sale, that's the best part. They have three drugs in four different trials so the odds of at least one succeeding is a lot higher than most other small biotechs out there.